<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META content="text/html; charset=iso-8859-1" http-equiv=Content-Type>
<META content="MSHTML 5.00.2614.3500" name=GENERATOR>
<STYLE></STYLE>
</HEAD>
<BODY background="" bgColor=#ffffff>
<DIV><FONT face=Arial size=2>Hola</FONT></DIV>
<DIV> </DIV>
<DIV><FONT face=Arial size=2>En el Pais Vasco, Sanidad está intentando atajar el
gasto que supone la prescripcion de otros IBP, al establecer en informes del
Comite de Evaluacion de Nuevos Medicamentos que las diferencias en efectividad
no son significativas, la seguridad es menos conocida (por ser medicamentos mas
nuevos) y su precio sensiblemente mas alto (sobre todo por la inexistencia de
EFG), frente a Omeprazol.</FONT></DIV>
<DIV><FONT face=Arial size=2></FONT> </DIV>
<DIV><FONT face=Arial size=2>Por ahora han mandado una circular a prescriptores
y farmacias informando, pero de no conseguir que la prescripcion no disminuya,
continuaran con ello (se habló de solicitar visado).</FONT></DIV>
<DIV> </DIV>
<DIV><FONT face=Arial size=2>Podeis consultar mas en
euskadi.net/sanidad</FONT></DIV>
<DIV> </DIV>
<DIV><FONT face=Arial size=2>Un saludo</FONT></DIV>
<DIV> </DIV>
<DIV><FONT face=Arial size=2>Imanol Monteagudo</FONT></DIV>
<DIV><FONT face=Arial size=2>Farmaceutico Comunitario</FONT></DIV>
<DIV><FONT face=Arial size=2>Vitoria</FONT></DIV>
<BLOCKQUOTE
style="BORDER-LEFT: #000000 2px solid; MARGIN-LEFT: 5px; MARGIN-RIGHT: 0px; PADDING-LEFT: 5px; PADDING-RIGHT: 0px">
<DIV style="FONT: 10pt arial">----- Original Message ----- </DIV>
<DIV
style="BACKGROUND: #e4e4e4; FONT: 10pt arial; font-color: black"><B>From:</B>
<A href="mailto:jrgarcia@uninet.edu" title=jrgarcia@uninet.edu>Jose Ramon
Garcia Solans</A> </DIV>
<DIV style="FONT: 10pt arial"><B>To:</B> <A href="mailto:AF@listas.uninet.edu"
title=AF@listas.uninet.edu>AF lista</A> </DIV>
<DIV style="FONT: 10pt arial"><B>Sent:</B> Wednesday, April 07, 2004 11:10
AM</DIV>
<DIV style="FONT: 10pt arial"><B>Subject:</B> [AF] Estudio comparativo de
IBP</DIV>
<DIV><BR></DIV>
<DIV><FONT face=Verdana size=2>Gracias a Rafa Bravo y la Biblioteca del
capitán Morgan, me entero de un metanalisis acerca de la diferencia de
efectividad y/o potencia de los inhibidores de la bomba de protones, cuyo
sumario adjunto. Traducido al castellano: todos los IBP son iguales (y sin
llegar a hablar de genéricos)</FONT></DIV>
<DIV><FONT face=Verdana size=2>Cordiales salu2:</FONT></DIV>
<DIV><FONT face=Verdana size=2>Jose Ramon Garcia Solans<BR>Farmaceutico
comunitario. Zaragoza<BR>976 554 986</FONT></DIV>
<DIV><BR><FONT face=Verdana size=2>Systematic review: direct comparative
trials of the efficacy of proton pump inhibitors in the management of
gastro-oesophageal reflux disease and peptic ulcer disease N. VAKIL* & M.
B. FENNERTY Departments of Medicine, Sections of Gastroenterology, *University
of Wisconsin, Milwaukee, WI, USA and Oregon Health and Science University,
Portland, OR, USA<BR>Accepted for publication 31 July
2003<BR>SUMMARY<BR>Background: Five proton pump inhibitors are now available
for use in North America. Claims of differences in the clinical efficacy of
different strengths and/or agents have been made.<BR>Aim: To identify any
consistent evidence of differences in outcomes between agents or doses within
this class of drugs.<BR>Methods: A search of the medical literature was
performed in two electronic databases, and randomized controlled trials of
higher quality were included in the assessment.<BR>Results and conclusions:
Thirty-two trials met our criteria. No convincing data were found to indicate
that low doses of proton pump inhibitors are as effective as standard doses of
proton pump inhibitors in the healing of erosive oesophagitis or in the relief
of symptoms of gastro-oesophageal reflux disease; however, they may be as
effective as maintenance therapy for gastro-oesophageal reflux disease and
peptic ulcer disease. Differences were found between the standard doses of
proton pump inhibitors with regard to the onset of symptom relief in
gastro-oesophageal reflux disease (lansoprazole was faster than
omeprazole, and esomeprazole was faster than both lansoprazole and omeprazole)
and the healing of oesophagitis (esomeprazole was superior to both omeprazole
and lansoprazole). <BR>Despite these differences, there are as yet
insufficient data to establish the superiority of any one agent over all
others across all disease states treated with these
agents.<BR><BR></FONT></DIV>
<P>
<HR>
<P></P>_______________________________________________<BR>Para iniciar un tema
escriba a: AF@listas.uninet.edu<BR>Para cambiar la configuración de su
suscripción hágalo en:
<BR>http://listas.uninet.edu/mailman/listinfo/af<BR></BLOCKQUOTE></BODY></HTML>